We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Brainstorm Cell Therapeutics Inc (BCLI) USD0.00005

Sell:$0.52 Buy:$0.53 Change: $0.02 (3.81%)
Market closed |  Prices as at close on 24 April 2024 | Switch to live prices |
Sell:$0.52
Buy:$0.53
Change: $0.02 (3.81%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 24 April 2024 | Switch to live prices |
Sell:$0.52
Buy:$0.53
Change: $0.02 (3.81%)
Market closed |  Prices as at close on 24 April 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

BrainStorm Cell Therapeutics Inc. is a developer of autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The neurodegenerative diseases include Amyotrophic Lateral Sclerosis (ALS), Progressive Multiple Sclerosis (PMS), Alzheimer’s disease (AD), and others. The Company is engaged in the clinical development and commercialization of the NurOwn technology platform used to produce autologous mesenchymal stem cells- neurotrophic factors (MSC-NTF) cells. NurOwn leverages cell culture methods to induce autologous bone marrow derived MSCs to secrete high levels of NTFs, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. Autologous MSC-NTF cells is for the treatment of ALS. It has completed a phase III trial in ALS. Its wholly owned subsidiary, BrainStorm Cell Therapeutics Ltd., holds exclusive rights to commercialize NurOwn technology.

Contact details

Address:
1325 Avenue Of Americas, 28Th Floor
NEW YORK
10019
United States
Telephone:
+1 (201) 4880460
Website:
https://brainstorm-cell.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
BCLI
ISIN:
US10501E2019
Market cap:
$35.88 million
Shares in issue:
68.34 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Jacob Frenkel
    Independent Chairman of the Board
  • Chaim Lebovits
    President, Chief Executive Officer
  • Stacy Lindborg
    Co-Chief Executive Officer
  • Alla Patlis
    Chief Financial Officer, Controller
  • Uri Yablonka
    Executive Vice President, Chief Business Officer, Secretary, Director
  • Ibrahim Dagher
    Executive Vice President, Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.